Mayo Clinic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mayo Clinic sits in the top decile of US sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count).
Mayo Clinic: 2,844 sponsored US clinical trials, 544 recruiting.
Mayo Clinic sponsors 2,844 registered US clinical trials on ClinicalTrials.gov, 544 of them currently recruiting, and 1,816 completed. 252 of these trials are in Phase 3-4 (later-stage) and 821 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 36 trials.
Top-decile sponsor footprint
Mayo Clinic ranks in the top decile of sponsors by registered trial count (#2 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,844 total, page 13 of 57
Ketamine and Kidney Injury in Cardiac Surgery
NCT05268562
Registry for Mayo Clinic Adult Congenital Heart Disease Control Population
NCT05773300
Minnesota RETAIN Phase 2 (Sub-study)
NCT05216016
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
NCT05167721
Targeting Inflammation for Endometrial Cancer Prevention
NCT05407025
Intrarenal Microvasculature in ADPKD
NCT05288998
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
NCT04856046
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
NCT05193981
Acute Recording of Stereotyped High-Frequency Oscillations
NCT05439655
A Study to Evaluate White Matter Hyperintensities in Migraine
NCT05112289
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
NCT04895735
Quality of Life Assessment Between Internal Endoscopic Versus Percutaneous Drainage in Biliary Obstruction
NCT04857424
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
NCT04926948
A Study to Compare the Effectiveness of Different High-intensity Interval Training Programs in Cardiac Rehabilitation
NCT04555512
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
NCT04897009
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
NCT04764942
Ultra-low-dose Chest CT for HHT
NCT04874558
Daratumumab to Treat Active Lupus Nephritis
NCT04868838
Cellular Senescence and COVID-19 Long-Hauler Syndrome
NCT04903132
Determining Molecular Drivers of Radiation Dermatitis
NCT04764682
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
NCT04640779
Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair
NCT04795934
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
NCT04607954
Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk
NCT04562480
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
NCT04574635
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
NCT04329039
Angiographic Delivery of AD-MSC for Ulcerative Colitis
NCT04312113
Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity
NCT04532814
A Study to Evaluate Renal Fibrosis Using MRI Techniques
NCT04508049
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
NCT04508907
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
NCT04476953
Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients
NCT04520373
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
NCT04443413
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
NCT04323956
Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer
NCT06326216
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
NCT04002583
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
NCT04007744
Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
NCT04028947
DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study
NCT05212428
Analysis of Biomarkers in Lymph Node Tissue
NCT04228796
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
NCT04190446
Myocardial Injury in Patients With Cardiac Implantable Electronic Devices Undergoing Defibrillation Threshold Testing
NCT04284800
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
NCT04197934
Cohort Study of Pancreatic Cancer Risk
NCT04247503
Intraoperative Costs and Patient Perceptions in Sacrocolpopexy for Prolapse
NCT04179955
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
NCT04112290
Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study
NCT04474834
Understanding Challenges, Behavioral Patterns, and Preferences Toward Participation in Clinical Trials in Minority Patient Populations: Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer Patients
NCT04630431
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer
NCT04308720
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
NCT04040088
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 435 |
| Phase 2 | 386 |
| Phase 3 | 86 |
| Phase 4 | 166 |
Therapeutic Areas
What is open in the Mayo Clinic pipeline
544 recruiting of 2,844 indexed (19% open); 1,816 completed (64%).
Phase mix: 252 late (III/IV) vs 821 early (I/II) (early-phase heavy).
Top condition: Healthy (36 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.